124 related articles for article (PubMed ID: 38713052)
1. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies.
Voutsadakis IA
Tissue Barriers; 2024 May; ():2348852. PubMed ID: 38713052
[TBL] [Abstract][Full Text] [Related]
2. EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.
Voutsadakis IA
Curr Issues Mol Biol; 2023 Jul; 45(7):6040-6054. PubMed ID: 37504297
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
[TBL] [Abstract][Full Text] [Related]
4. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
5. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer.
Nishijima TF; Kardos J; Chai S; Smith CC; Bortone DS; Selitsky SR; Parker JS; Sanoff HK; Lee MS; Vincent BG
JCO Precis Oncol; 2017 Nov; 1():1-10. PubMed ID: 35172495
[TBL] [Abstract][Full Text] [Related]
6. Nuclear staining of claudin-18 is a new immunohistochemical marker for diagnosing intramucosal well-differentiated gastric adenocarcinoma.
Takahashi Y; Tsutsumi Y; Takeuchi C; Shiogama K; Mizutani Y; Inada KI; Yamamichi N; Koike K
Pathol Int; 2020 Sep; 70(9):644-652. PubMed ID: 32623829
[TBL] [Abstract][Full Text] [Related]
7. Tight Junction Claudins and Occludin Are Differentially Regulated and Expressed in Genomically Defined Subsets of Colon Cancer.
Voutsadakis IA
Curr Issues Mol Biol; 2023 Oct; 45(11):8670-8686. PubMed ID: 37998722
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
9. Claudin 18.2 as a novel therapeutic target.
Nakayama I; Qi C; Chen Y; Nakamura Y; Shen L; Shitara K
Nat Rev Clin Oncol; 2024 May; 21(5):354-369. PubMed ID: 38503878
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.
Voutsadakis IA
Cancer Genomics Proteomics; 2023; 20(6):539-555. PubMed ID: 37889067
[TBL] [Abstract][Full Text] [Related]
11. The Landscape of PIK3CA Mutations in Colorectal Cancer.
Voutsadakis IA
Clin Colorectal Cancer; 2021 Sep; 20(3):201-215. PubMed ID: 33744168
[TBL] [Abstract][Full Text] [Related]
12. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation.
Resnick MB; Gavilanez M; Newton E; Konkin T; Bhattacharya B; Britt DE; Sabo E; Moss SF
Hum Pathol; 2005 Aug; 36(8):886-92. PubMed ID: 16112005
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.
Voutsadakis IA
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345027
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines.
Ogawa M; Kojima T; Someya M; Nomura K; Takasawa A; Murata M; Tanaka S; Saito T; Sawada N
Histochem Cell Biol; 2012 Aug; 138(2):323-38. PubMed ID: 22544349
[TBL] [Abstract][Full Text] [Related]
15. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
16. Claudin-18 Loss Alters Transcellular Chloride Flux but not Tight Junction Ion Selectivity in Gastric Epithelial Cells.
Caron TJ; Scott KE; Sinha N; Muthupalani S; Baqai M; Ang LH; Li Y; Turner JR; Fox JG; Hagen SJ
Cell Mol Gastroenterol Hepatol; 2021; 11(3):783-801. PubMed ID: 33069918
[TBL] [Abstract][Full Text] [Related]
17.
Voutsadakis IA
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33435133
[TBL] [Abstract][Full Text] [Related]
18. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front.
Oshima T; Shan J; Okugawa T; Chen X; Hori K; Tomita T; Fukui H; Watari J; Miwa H
PLoS One; 2013; 8(9):e74757. PubMed ID: 24073219
[TBL] [Abstract][Full Text] [Related]
20. Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-Talk between HNF1A and HNF4A, and Upregulated Cholesterol Metabolism.
Dwivedi S; Hernández-Montes G; Montaño LF; Rendón-Huerta EP
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
